pyridoxine has been researched along with Cancer of Ovary in 6 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In vitro simultaneous combination of OHP and pyridoxine was studied in 6 CRC cell lines (HT29, Widr, SW480, HCT116, H630 and SW1116), in an ovarian cancer cell line (A2780) and its cisplatin-resistant subline (ADDP) and in an oestrogen-dependent breast cancer cell line (MCF-7)." | 3.77 | Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect. ( Ackland, SP; Garg, MB, 2011) |
| " This study demonstrates that the combination of DDP + HMM is an effective regimen for advanced ovarian carcinoma that yields response rates comparable to other more complex regimens, and that there is a dose-response relationship for DDP in ovarian cancer." | 2.67 | Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. ( Cheuvart, B; Comis, RL; Davis, TE; Falkson, G; Fazzini, E; Horton, J; Kaplan, BH; Vogl, SE; Wiernik, PH; Yeap, B, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garg, MB | 1 |
| Ackland, SP | 1 |
| Wharton, JT | 1 |
| Rutledge, F | 1 |
| Smith, JP | 1 |
| Herson, J | 1 |
| Hodge, MP | 1 |
| Wiernik, PH | 1 |
| Yeap, B | 1 |
| Vogl, SE | 1 |
| Kaplan, BH | 1 |
| Comis, RL | 1 |
| Falkson, G | 1 |
| Davis, TE | 1 |
| Fazzini, E | 1 |
| Cheuvart, B | 1 |
| Horton, J | 1 |
| Ladner, HA | 1 |
| Salkeld, RM | 1 |
| Monchenko, GD | 1 |
| Pruttseva, NV | 1 |
| Picha, E | 1 |
1 review available for pyridoxine and Cancer of Ovary
| Article | Year |
|---|---|
Vitamin B6 status in cancer patients: effect of tumor site, irradiation, hormones and chemotherapy.
Topics: Breast Neoplasms; Estrogens; Female; Genital Neoplasms, Female; Humans; Neoplasms; Ovarian Neoplasms | 1988 |
1 trial available for pyridoxine and Cancer of Ovary
| Article | Year |
|---|---|
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 1992 |
4 other studies available for pyridoxine and Cancer of Ovary
| Article | Year |
|---|---|
Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Cos | 2011 |
Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
Topics: Adult; Altretamine; Female; Hematologic Diseases; Humans; Ovarian Neoplasms; Peripheral Nervous Syst | 1979 |
[Efficacy of preoperative correction of metabolic acidosis with neoplastic processes in different sites].
Topics: Acidosis; Adult; Aged; Ascorbic Acid; Female; Glucose; Humans; Insulin; Intestinal Neoplasms; Lung N | 1971 |
[Possibility for the favorable influencing of convalescence following gynecologic radiotherapy].
Topics: Androstanes; Androstenols; Ascorbic Acid; Cobalt Isotopes; Convalescence; Cystine; Drug Synergism; F | 1968 |